Zoetis Inc.
ZTSHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeZoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions. The $32.57B market capitalization puts ZTS squarely in large-cap range for its industry. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep.
Market Cap
$32.57B
Beta
0.86
P/E (TTM)
12.74
P/E (Fwd)
10.46
EPS (TTM)
$6.10
EPS (Fwd)
$7.42
ROE
67.8%
ROA
15.5%
Cash
$1.94B
Total Debt
$9.25B
Free CF
$1.78B
52W Change
-54.1%
Annual Financials
Cash vs Debt
On the balance sheet, ZTS has $1.94B in cash with $9.25B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $1.78B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 67.8%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 15.5% further supports the picture of efficient asset utilization. Revenue has been uneven over recent years, ranging from $8.08B to $9.47B.
As with any equity investment, ZTS carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Zoetis Inc. and its sector.